ClinicalTrials.Veeva
Menu

Find clinical trials for Melanoma in Hanyang, Seoul

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Non-Small-Cell Lung Carcinoma
Renal Cell Carcinoma
Lung Cancer
Squamous Cell Carcinoma

Melanoma trials near Hanyang, Seoul, KOR:

Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6

This study observes the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma...

Enrolling
Mucosal Melanoma
Cutaneous Melanoma
Drug: Nemvaleukin Alfa Intravenous Less Frequent Dosing
Drug: Nemvaleukin Alfa Intravenous

Phase 2

Mural Oncology

Seoul, Seocho-gu, Korea, Republic of and 40 other locations

(PK) similarity and efficacy, safety, and immunogenicity of ABP 206 compared with OPDIVO® (nivolumab) in subjects with resected advanced melanoma...

Enrolling
Melanoma
Drug: EU-authorized Nivolumab
Drug: ABP 206

Phase 3

Amgen
Amgen

Seoul, Seoul Teugbyeolsi [Seoul-T'ukp, Korea, Republic of and 108 other locations

safety, pharmacokinetics, and preliminary efficacy of the investigational drug PLX3397 in subjects with unresectable or metastatic KIT-mutated melanoma...

Active, not recruiting
Melanoma
Drug: PLX3397
Daiichi Sankyo
Daiichi Sankyo

Seoul, Korea, Republic of and 4 other locations

of ceralasertib, when administered as monotherapy and in combination with durvalumab in participants with unresectable or advanced melanoma ...

Active, not recruiting
Melanoma
Drug: Ceralasertib
Biological: Durvalumab

Phase 2

AstraZeneca
AstraZeneca

Seoul, Korea, Republic of and 63 other locations

combined with nivolumab on patients with unresectable or metastatic melanoma and eligible patients who are not adolescents or patients with ...

Enrolling
Unresectable or Metastatic Melanoma
Progressive Brain Metastasis
Drug: Placebo in combination with nivolumab
Drug: HBI-8000 in combination with nivolumab

Phase 3

HUYABIO

Seoul, Gyeonggi-do, Korea, Republic of and 141 other locations

The purpose of this study is to determine whether nivolumab is better than ipilimumab to prevent recurrence of melanoma....

Active, not recruiting
Melanoma
Drug: Nivolumab
Other: Placebo matching Nivolumab

Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Seoul, Korea, Republic of and 135 other locations

belvarafenib as a single agent and in combination with either cobimetinib or cobimetinib plus nivolumab in patients with NRAS-mutant advanced melanoma...

Active, not recruiting
Melanoma
Drug: Belvarafenib
Drug: Cobimetinib

Phase 1

Genentech
Genentech

Seoul, Korea, Republic of and 23 other locations

to pembrolizumab with respect to RFS as assessed by the investigator in participants with high-risk resected Stage IIB, IIC, III and IV melanoma...

Active, not recruiting
Melanoma
Biological: Pembrolizumab/Vibostolimab
Biological: Pembrolizumab

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Seoul, Korea, Republic of and 204 other locations

in patients with locally advanced unresectable or metastatic melanoma with BRAF V600 mutation. A total of approximately 900 patients will be...

Active, not recruiting
Melanoma
Drug: MEK162
Drug: vemurafenib

Phase 3

Pfizer
Pfizer

Seoul, Korea, Republic of and 378 other locations

+ cobimetinib + vemurafenib in patients with previously untreated BRAFv600 mutation-positive metastatic or unresectable locally advanced melanoma...

Active, not recruiting
Melanoma
Drug: Atezolizumab Placebo
Drug: Vemurafenib

Phase 3

Roche
Roche

Seoul, Korea, Republic of and 115 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems